1. Scrip
  2. >>Leadership

Teva CEO Steps Down While An Integration Hangs In The Balance

 
• By Jessica Merrill

After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.

Clouds-Lightning-Storm_1200x675

The departure of Teva Pharmaceutical Industries Ltd. CEO Erez Vigodman leaves the Israeli generic drug giant without both of the two primary architects of its $40.5bn acquisition of Allergan PLC’s generics business in 2016, potentially posing risks to the integration.

Vigodman will step down almost three years to the day after he took the helm, having failed to turn around...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Peter Marks Brings Genetic Medicines Street Cred To Lilly

 
• By Jessica Merrill

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.

Executives On The Move: Three New CEOs And CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Integra LifeSciences, plus Zealand Pharma gets a new senior executive from Novartis.

A Backroom Deal Leaves Questions About How Pfizer’s US Agreement Lowers Prices

 
• By Jessica Merrill

By choosing a confidential agreement with the US government over announcing a transparent drug pricing deal, Pfizer continues industry’s legacy of pricing secrecy.

A VC Perspective On Korean Bioventures: New Catalysts Needed To Jumpstart Activity

 
• By Jung Won Shin

Stonebridge Ventures’ managing director Hyun-Ki Kim talks to Scrip on factors constraining the recovery of VC funding in Korean bioventures and its investment considerations, strategies and priorities.

More from Scrip

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 
• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.